BiotechTube
Ferring Pharmaceuticals

Ferring Pharmaceuticals

Prague, Czech Republic· Est.
ferringusa.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Ferring Pharmaceuticals is a global, private biopharmaceutical company founded in 1950 and headquartered in Saint-Prex, Switzerland, with a significant operational presence in Prague, Czech Republic. The company focuses on high-need therapeutic areas, with a strong commercial portfolio and pipeline in reproductive medicine, uro-oncology, gastroenterology, and orthopaedics. Its recent strategic activities include label expansions for its gene therapy ADSTILADRIN, real-world evidence generation for its microbiome therapeutic REBYOTA, and entering into new clinical collaborations in bladder cancer.

Reproductive MedicineUro-oncologyGastroenterologyOrthopaedics

Technology Platform

Applied R&D across multiple modalities including gene therapy (adenovirus vector), live biotherapeutic/microbiome, and recombinant hormone technology.

Opportunities

Significant growth potential from the launch and label expansion of its gene therapy ADSTILADRIN in a bladder cancer setting with high unmet need.
The emerging microbiome therapeutics market, where REBYOTA is a first-to-market product, offers a major new revenue stream.
Continued demand in reproductive medicine provides a stable financial foundation for investing in innovative pipeline programs.

Risk Factors

Commercial and pipeline reliance on key assets like ADSTILADRIN exposes the company to product-specific risks.
Intense competition in all core therapeutic areas (fertility, oncology, microbiome) pressures market share and pricing.
Navigating complex U.S.
reimbursement and market access environments for high-cost specialty therapies remains a persistent challenge.

Competitive Landscape

In uro-oncology, Ferring's ADSTILADRIN competes with other intravesical therapies and emerging systemic options for BCG-unresponsive NMIBC. In reproductive medicine, it faces numerous established players in the crowded fertility drug market. In the microbiome space, REBYOTA competes with other fecal microbiota products and orally administered microbiome therapies for recurrent C. diff.

More companies in Biologics / Biosimilars →More companies in Czech Republic →